Kelun-Biotech Maintains Stable Share Structure in March 2026 Monthly Return

Bulletin Express

Apr 09

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (H-share abbreviation: Kelun-Biotech) reported no changes in authorised, registered or issued share capital for the month ended 31 March 2026.

• Authorised/registered capital remained unchanged at 233.19 million shares with a par value of RMB1.00 each, comprising: – 162.77 million H shares listed in Hong Kong – 65.77 million domestic shares – 4.64 million unlisted foreign shares

• Issued share capital mirrored the authorised totals, and no treasury shares were held at month-end.

• Public float for the H-share class met the minimum 22.09 % requirement under Main Board Rule 13.32B, confirming sufficient market liquidity.

• There were no movements involving share options, warrants, convertibles, or other equity instruments during the month.

Joint Company Secretary Zhou Zejian submitted the return on 9 April 2026, confirming compliance with all applicable listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1100945432"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100945432\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100945432?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100945432","market":"us","top_or_hot":-1,"title":"Kelun-Biotech Maintains Stable Share Structure in March 2026 Monthly Return","media":"Bulletin Express","content":"<p>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (H-share abbreviation: Kelun-Biotech) reported no changes in authorised, registered or issued share capital for the month ended 31 March 2026.</p>\n<p>• Authorised/registered capital remained unchanged at 233.19 million shares with a par value of RMB1.00 each, comprising:  \n – 162.77 million H shares listed in Hong Kong  \n – 65.77 million domestic shares  \n – 4.64 million unlisted foreign shares</p>\n<p>• Issued share capital mirrored the authorised totals, and no treasury shares were held at month-end.</p>\n<p>• Public float for the H-share class met the minimum 22.09 % requirement under Main Board Rule 13.32B, confirming sufficient market liquidity.</p>\n<p>• There were no movements involving share options, warrants, convertibles, or other equity instruments during the month.</p>\n<p>Joint Company Secretary Zhou Zejian submitted the return on 9 April 2026, confirming compliance with all applicable listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kelun-Biotech Maintains Stable Share Structure in March 2026 Monthly Return</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKelun-Biotech Maintains Stable Share Structure in March 2026 Monthly Return\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-09 16:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (H-share abbreviation: Kelun-Biotech) reported no changes in authorised, registered or issued share capital for the month ended 31 March 2026.</p>\n<p>• Authorised/registered capital remained unchanged at 233.19 million shares with a par value of RMB1.00 each, comprising:  \n – 162.77 million H shares listed in Hong Kong  \n – 65.77 million domestic shares  \n – 4.64 million unlisted foreign shares</p>\n<p>• Issued share capital mirrored the authorised totals, and no treasury shares were held at month-end.</p>\n<p>• Public float for the H-share class met the minimum 22.09 % requirement under Main Board Rule 13.32B, confirming sufficient market liquidity.</p>\n<p>• There were no movements involving share options, warrants, convertibles, or other equity instruments during the month.</p>\n<p>Joint Company Secretary Zhou Zejian submitted the return on 9 April 2026, confirming compliance with all applicable listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1100945432","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100945432","pubTimestamp":1775724073,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (H-share abbreviation: Kelun-Biotech) reported no changes in authorised, registered or issued share capital for the month ended 31 March 2026. •...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"科伦生物2026年3月股权结构保持稳定月报表","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (H-share abbreviation: Kelun-Biotech) reported no changes in authorised, registered or issued share capital for the month ended 31 March 2026.\n• Authorised/registered capital remained unchanged at 233.19 million shares with a par value of RMB1.00 each, comprising:  \n – 162.77 million H shares listed in Hong Kong  \n – 65.77 million domestic shares  \n – 4.64 million unlisted foreign shares\n• Issued share capital mirrored the authorised totals, and no treasury shares were held at month-end.\n• Public float for the H-share class met the minimum 22.09 % requirement under Main Board Rule 13.32B, confirming sufficient market liquidity.\n• There were no movements involving share options, warrants, convertibles, or other equity instruments during the month.\nJoint Company Secretary Zhou Zejian submitted the return on 9 April 2026, confirming compliance with all applicable listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}